

1 **A multiplex serological assay for the characterization of IgG immune response to SARS-**  
2 **CoV-2**

3  
4 Etienne Brochot<sup>a,b\*</sup>, Vianney Souplet<sup>c\*</sup>, Pauline Follet<sup>c</sup>, Pauline Ponthieu<sup>c</sup>, Christophe Olivier<sup>c</sup>,  
5 Gaël Even<sup>d</sup>, Christophe Audebert<sup>d</sup>, Rémi Malbec<sup>d</sup>

6  
7 <sup>a</sup> Department of Virology, Amiens University Medical Center, Amiens, France

8 <sup>b</sup> Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University  
9 of Picardie, France

10 <sup>c</sup> Innobiochips, 70 rue du Dr Yersin, 59120 Loos, France

11 <sup>d</sup> GD Biotech, 3595 Route de Tournai, 59501 Douai, France

12

13

14

15

16

17

18

19 \*Corresponding authors:

20 Etienne Brochot, [Brochot.Etienne@chu-amiens.fr](mailto:Brochot.Etienne@chu-amiens.fr); Vianney Souplet  
21 [vianney.souplet@innobiochips.fr](mailto:vianney.souplet@innobiochips.fr)

22

## 23 **Abstract**

24 *Background:* In the fight against SARS-COV-2, the development of serological assays based on  
25 different antigenic domains represent a versatile tool to get a comprehensive picture of the immune  
26 response or differentiate infection from vaccination beyond simple diagnosis.

27 *Objectives:* Here we use a combination of the Nucleoprotein (NP), the Spike 1 (S1) and Spike 2  
28 (S2) subunits, and the receptor binding domain (RBD) and N-terminal domain (NTD) of the Spike  
29 antigens from the Sirius-CoViDiag<sup>®</sup> multiplex IgG assay, to follow the immune response to  
30 SARS-CoV-2 infection over a long time period and depending on disease severity.

31 *Results:* Using a panel of 209 sera collected from 61 patients up to eight months after infection,  
32 we observed that most patients develop an immune response against multiple viral epitope, but  
33 anti-S2 antibodies seemed to last longer. For all the tested IgGs, we have found higher titers for  
34 hospitalized patients than for non-hospitalized ones. Moreover the combination of the five  
35 different IgG titers increased the correlation to the neutralizing antibody titers than if considered  
36 individually.

37 *Conclusion:* Multiplex immunoassays have the potential to improve diagnostic performances,  
38 especially for ancient infection or mild form of the disease presenting weaker antibody titers. Also  
39 the combined detection of anti-NP and anti-Spike-derived domains can be useful to differentiate  
40 vaccination from viral infection and accurately assess the antibody potential to neutralize the virus.

41

42

43 **Key words:** SARS-CoV-2, COVID-19, Serological assays, Multiplexing, IgG profile

44

45

## 46 **1. Introduction**

47           Since its first detection in Wuhan (China) in December 2019, the Severe Acute Respiratory  
48    Syndrome Coronavirus 2 (SARS-CoV-2) has rapidly spread to reach other countries worldwide as  
49    the coronavirus 2019 disease (COVID-19) became pandemic (1).

50           The virion has a nucleocapsid composed by genomic RNA and phosphorylated  
51    Nucleocapsid (NP) protein, which is buried inside a phospholipid bilayer and covered by the Spike  
52    proteins trimmers (S) that gives the CoVs their crown-like appearance on which their names are  
53    based. The S protein has two subunits, the Spike 1 (S1) which contains the receptor-binding  
54    domain (RBD) and N-terminal domain (NTD) and the Spike 2 (S2) (2). The choice of the antigenic  
55    domain is important, as it must be specific to the SARS-CoV-2 for discrimination against other  
56    hCoVs for example, and sensitive enough so infection would not be missed (Brochet et al., 2020).  
57    Also, anti-RBD antibodies are known to play a role in patients protection as this domain is used  
58    by the virus to penetrate host cells (4). Most commercial serological assays have demonstrated  
59    satisfying performances in terms of diagnostic sensitivity and specificity, based on one of those  
60    main different antigenic domains (5,6). However, the combination of different immunogenic  
61    antigens can give a more comprehensive picture of the humoral response strength and diversity  
62    (7–9) while maintaining elevated diagnostic performances (10,11). In multiplex assays, positivity  
63    thresholds can be adjusted to compensate for the use of antigenic domains more conserved between  
64    coronaviruses (12). Moreover, as vaccines are based on the Spike protein, the additional detection  
65    of anti-NP antibodies allows to differentiate viral infection from vaccination.

66           This study reports the design and use of the Syrius-CoViDiag<sup>®</sup> multiplex IgG assay for the  
67    characterization of the immune response against over time, depending on disease severity, and in  
68    perspective of neutralizing antibody titers.

## 69 2. Material and Methods

### 70 2.1. Study design and cohort

71 The study was conducted at Amiens University medical Center (France). Samples were  
72 derived from de-identified excess serum specimens. The demographic information of the patients  
73 are available in Table 1. The study was approved by the institutional review board of the Amiens  
74 University Medical Center (number PI2020\_843\_0046, 21 April 2020).

75 Briefly, we used n=209 samples collected between March and April 2020 from n=61 patients  
76 (27 hospitalized patients and 34 non-hospitalized patients) with PCR-confirmed SARS-CoV-2  
77 infections to perform immunoassay and virus seroneutralization test as already described in Aubry  
78 et al., 2021. All samples have been tested according to manufacturer's instruction on the SirYus-  
79 CoViDiag® serological assay and the raw results are available in supplementary data.

80

81 **Table 1. Cohort Characteristics.**

Number of patients	61
Female	36
Male	25
Age (Years): Median Range	74 26-98
>65 years	41
Hospitalized patients	27
Nonhospitalized patients	34
Immunocompromised patients	6 (2 kidney transplant, 2 bone marrow transplant, 2 chemotherapy)

---

Number of samples (days post-PCR)	
0-59	52
60-119	49
120-179	49
≥180	59

---

Number of patients (days post-PCR)	
0-59	50
60-119	36
120-179	42
≥180	46

---

82

## 83 2.2. Serological assay

84 The SirYus-CoViDiag® multiplex immunoassay targets IgG antibodies against five different  
85 antigens of the virus: NP, S1, S2, RBD, and NTD (Fig. 1). Note that the S1 and NP antigens have  
86 been printed in dot replicates in the shape of an “S” and “N” letters, respectively. This design  
87 allows for quick visual interpretation of seropositivity and vaccination status. The results have  
88 been automatically delivered using the SciReader® plate reader (Scenion GmbH) and associated  
89 analysis software, and an algorithm combining different cut-offs for the different antigens  
90 according to the manufacturer instructions. The spot mean signal intensity (MSI) was calculated  
91 as the average pixel value inside the spot perimeter minus the local background around the spot as  
92 described in Malbec et al., 2020. When multiplexing, the positivity thresholds can be adjusted with  
93 the number of different IgG antibodies detected. As NP and S2 antigens are more conserved  
94 between coronaviruses, SARS-CoV-2 IgG positivity is declared when a single one of them gives  
95 a signal over 40 MSI. However when NP and S2 antibodies are concomitantly present, the cut-off  
96 is adjusted to 20 MSI. For S1, RBD, and NTD antibodies a cut-off of 10 MSI is applied for SARS-  
97 CoV-2 positivity. Based on this algorithm, the test has been accredited by the French National  
98 Reference Center (CNR) in August 2020. On a reference cohort of 48 sera from patients positive  
99 to Covid-19 and 48 sera from patients negative to Covid-19. 14 days post symptoms, the diagnostic  
100 sensitivity was 90 %. The diagnostic specificity was 100 %.

101

102 **Figure 1. Full well pictures pictures obtained with the microplate reader (SciReader<sup>®</sup>) or with a**  
103 **phone camera (in insert) after incubation with the CoViDiag<sup>®</sup> assay. (A) Positive sample presenting**  
104 **antibodies against the Nucleopcapside (NP), Spike 1 (S1), N-terminal domain (NTD) and Receptor binding**  
105 **domain (RBD) of the Spike protein, or Spike 2 (S2) antigens. (B) Negative sample with positive control on**  
106 **the edges. Scale bars correspond to 1 mm.**

107

### 108 *2.3. Statistical analysis*

109 For the statistical analysis, Student's test was used to test the relationship between different  
110 categorical variables and the difference in antibody MSI between hospitalized and non-  
111 hospitalized groups of patients. Spearman's rank Correlation test was used to test the correlation  
112 between different antibody MSI and dilution factor for the neutralization assay. The general  
113 significance level was set at a p-value below 0.05. All analyses were performed using packages  
114 stats from the R statistical computing program v. 3.6.1 (Date of release 07/05/2019).

115

## 116 **3. Results**

### 117 *3.1. Evolution of the IgG profile over time*

118 Using the SirYus-CoViDiag<sup>®</sup> assay on 209 serum samples, the seropositivity stayed stable  
119 around 90 % for 6 months after an initial positive SARS-CoV-2 RT-PCR, before decreasing to  
120 83.1 % between six and eight months (Fig. 2A).

121

122 **Figure 2. Evolution of the IgG profile over time. (A) Percentage of patients CoViDiag positive to anti-**  
123 **NP, anti-S1, anti-S2, anti-RBD, and anti-NTD IgG antibodies and (B) associated average IgG titers.**

124 Positivities for each IgG considered individually are also reported based on the cut-offs set  
125 by the manufacturer. 54.1 % (n=113/209) samples were concomitantly positives for anti-NP, anti-  
126 S1, anti-S2 and anti-RBD antibodies and 9.1 % (n=19/209) for all 5 antibodies. 4.3 % (n=9/209)  
127 samples were positives for a single antibody (n=6 for anti-NP, n=2 for anti-S1 and n=1 for anti-  
128 S2) (Table 2). 80.9 % (n=169/209) samples were positives to anti-NP antibodies, allowing  
129 potential differentiation of infection from vaccination.

130

131 **Table 2. Prevalence of the profile of IgG immune response.** Percentage of positivity for antibodies  
132 against different antigens or combinaison of antigens.

	N	% Seroprevalence
Samples	209	
Single antibody		
<i>NP</i>	6	2.9
<i>S1</i>	2	1.0
<i>S2</i>	1	0.5
<i>RBD</i>	0	0
<i>NTD</i>	0	0
<i>Total</i>	9	4.3
Combinaison of antibodies*		
<i>NP+S2</i>	5	2.4
<i>NP+S1+S2</i>	5	2.4
<i>NP + S1 + RBD</i>	6	2.9
<i>NP+S2+RBD</i>	13	6.2
<i>S1+S2+RBD</i>	6	2.9

<i>NP+S1+S2+RBD</i>	113	54.1
<i>NP+S1+S2+RBD+NTD</i>	19	9.1

---

133 \* For clarity purpose, only most common combinaisons with >2% seroprevalence are reported.

134

135 The kinetics of the IgG serum antibody response to individual antigens are presented in  
136 Fig. 2B. Average MSIs have been calculated for all samples depending on the time post RT-PCR  
137 to SARS-CoV-2. The anti-NP and anti-NTD antibody responses were the first to decrease, as  
138 their MSI started to decline after just two months (-0.9 % and -8.1 % between two and four  
139 months, respectively). The anti-S1 and anti-RBD response peaked after four months, before  
140 significantly decreasing over time (-7.8 % and -13 % between four and six months,  
141 respectively). The anti-S2 antibody response was the most delayed, with a peak level reached  
142 between four and six months. The different dynamics observed show the interest of detecting  
143 IgG response against multiple immunogenic domains to maintain elevated diagnostic sensitivity,  
144 especially long after infection.

145

### 146 *3.2. IgG profile depending on the disease severity*

147 Then we have investigated the ability for the multiplex assay to differentiate hospitalized  
148 (severe cases) versus non hospitalized (mild cases) patients, based on the first sample collected  
149 for each of the 61 patients in the early convalescent phase of the disease. For all five  
150 immunogenic domains, the MSI, corresponding to the levels of antibody are plotted in Fig. 3,  
151 depending on disease severity. For each given antigen, we have observed a trend of greater  
152 antibody response for hospitalized patients (MSI: NP= 56.5 ; S1=49.1 ; S2=59.4 ; RBD=54.8 ;  
153 NTD= 11.8; Average=46.3) compare to non-hospitalized ones (MSI: NP= 51.8 ; S1=37.4 ;  
154 S2=49.2 ; RBD=47.1 ; NTD=4.3 ; Average=37.9). However, the differences were not statistically



155 different (p-value > 0.05, see supplementary Table 1).

156

157 **Figure 3. IgG profile depending on disease severity outcome.** Distribution of the different IgG titers  
158 based on the MSI, considered individually, or altogether (average) for hospitalized (n=25) and non-  
159 hospitalized patients (n=34) just after infection.

160

161 *3.3. Correlation between IgG profile and neutralizing antibody titers.*

162 Finally, we have evaluated the ability for the correlation between the different IgG levels  
163 response and the seroneutralization potential of the samples. For all five immunogenic domains,  
164 the mean intensity, corresponding to the levels of antibody response are plotted in Fig. 4  
165 depending on the highest dilution of serum resulting in a 90 % decrease in infectivity. As  
166 expected, the best correlation (see supplementary Table 2) between individual IgGs and  
167 neutralizing antibody response was obtained for anti-RBD antibodies ( $r^2=0.72$ ). The correlation  
168 was very similar between anti-S1 ( $r^2=0.67$ ) and anti-S2 ( $r^2=0.66$ ) antibodies. However Anti-NP  
169 ( $r^2=0.59$ ) and anti-NTD ( $r^2=0.47$ ) antibodies titers were less correlated with the neutralizing  
170 antibody titers. Interestingly, the combination of the 5 different antibody responses, allowed to  
171 slightly increase the correlation to ( $r^2=0.74$ ).

172

173 **Figure 4. Correlation of the different IgG titers with serum neutralization titers.** IgGs titers are based  
174 on the MSI considered individually, or altogether (average). Neutralizing antibody titers are based on the  
175 serum dilution factor to neutralize 90 % of infected cells.

176

177 **4. Discussion**

178 In a previous study based on the same set of sample, we have found equivalent to improved  
179 diagnostic performances, especially for ancient infections, for the CoViDiag® multiplex IgG  
180 assay compare to other IgG commercial serological assays (13). It is now generally admitted that  
181 antibody levels are weaker for asymptomatic and mild form of the disease and can decrease over  
182 time (8). Hence in the present work, we have investigated the detailed profile of the IgG immune  
183 response over an eight months period in a multiplex assay, using samples of hospitalized and  
184 non-hospitalized patients. Then we have compared the results with neutralizing antibody levels.

185 We have observed that most patients develop a global immune response against multiple  
186 immunogenic domains. Even over a 8 months period, more than a half of the samples were  
187 positives to anti-NP, anti-S1, anti-S2, and anti-RBD antibodies, concomitantly. Those result  
188 confirm the possibility to develop serological assays based on different antigens. Anti-NTD  
189 antibodies are more scarce but most patients SARS-CoV-2 infected develop antibodies against  
190 the NP antigen allowing potential differentiation of infection from vaccination.

191 As expected, the different IgGs titers decreased over time, but with different dynamics.  
192 Elevated levels of anti-S2 seem to last longer. Therefore the detection of anti-S2 antibodies may  
193 be of interest to maintain elevated diagnostic sensitivity longer after infection. The evolution of  
194 anti-S1 and anti-RBD titers is very similar, as RBD constitutes a domain of the Spike 1 protein.

195 For all the tested IgGs, we have found higher titers for hospitalized patients than for non-  
196 hospitalized ones. However, the differences were not statistically significant as a large number of  
197 patients had no immune response detected for individual antigens, independently of the disease  
198 severity.

199 It is noteworthy that most commercial assays performances have been established at the  
200 beginning of the epidemic, when samples from hospitalized patients were the easier to collect.

201 For people presenting a weaker immune response, multiplexing allows to test for extra domains  
202 that may help to slightly increase diagnostic sensitivity without compromising for diagnostic  
203 specificity.

204 Except for anti-NTD antibodies, all different IgGs titers were positively correlated with  
205 the neutralizing antibody titers. This result is not surprising considering our previous observation  
206 showing that anti-NP, anti-S1, anti-S2, and anti-RBD antibodies are concomitantly present in  
207 patient's sera. As expected, the best correlation for individual antigen is obtained for antibodies  
208 targeting the virus RBD domain which is known to be involved in the penetration of the cells by  
209 the virus. However the average combination of all five antigens slightly increased the  
210 correlation, strengthening the interest for multiplexing.

211

## 212 **5. Conclusion**

213 Beyond the diagnosis of SARS-COV-2 infection, tools delivering a global picture of the  
214 patients' immune response may also be of interest to improve the management and care of the  
215 patients and populations. Our results show that elevated IgGs titers against multiple viral epitope  
216 may be more characteristic of symptomatic patients, and correlates well with neutralizing  
217 antibodies. We recommend using assays targeting IgGs for the evaluation of a long lasting  
218 population protection and collective immunity. Furthermore, multiplexed assays have the  
219 potential to slightly increase diagnostic performances, especially for ancient or weak infections  
220 and be more representative of immune protection. For future epidemical studies, as the  
221 vaccination based on the Spike protein progresses, multiplex serological assays may also help to  
222 differentiate vaccination from viral infection.

223

224 **Funding**

225 **Laboratory's own resources**

226

227 **Declaration of competing interest**

228 Authors Rémi Malbec, Gaël Even and Christophe Audebert are employees of GD Biotech, while

229 Pauline Ponthieu, Pauline Follet, Vianney Souplet and Christophe Olivier are employees of

230 Innobiochips, providing the CoViDiag® assay kits for this study.

231

232 **References**

- 233 1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak  
234 associated with a new coronavirus of probable bat origin. *Nature*. mars  
235 2020;579(7798):270-3.
- 236 2. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune  
237 responses. *Journal of Medical Virology*. 2020;92(4):424-32.
- 238 3. Brochot E, Demey B, Touze A, Belouzard S, Dubuisson J, Schmit J-L, et al. Anti-Spike,  
239 anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 hospitalized patients and  
240 asymptomatic carriers [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2020 mai [cité 20  
241 mai 2020]. Disponible sur: <http://medrxiv.org/lookup/doi/10.1101/2020.05.12.20098236>
- 242 4. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The  
243 receptor binding domain of the viral spike protein is an immunodominant and highly  
244 specific target of antibodies in SARS-CoV-2 patients. *Sci Immunol*. 11 juin  
245 2020;5(48):eabc8413.
- 246 5. Brochot E, Demey B, Handala L, François C, Duverlie G, Castelain S. Comparison of  
247 different serological assays for SARS-CoV-2 in real life. *J Clin Virol*. sept  
248 2020;130:104569.
- 249 6. Tuaille E. Detection of SARS-CoV-2 antibodies using commercial assays and  
250 seroconversion patterns in hospitalized patients. *medRxiv*. 12 mai  
251 2020;2020.05.04.20090027.
- 252 7. Coste AT, Jatou K, Papadimitriou-Olivgeris M, Greub G, Croxatto A. Comparison of  
253 SARS-CoV-2 serological tests with different antigen targets [Internet]. *Infectious Diseases*  
254 (except HIV/AIDS); 2020 juill [cité 20 juill 2020]. Disponible sur:  
255 <http://medrxiv.org/lookup/doi/10.1101/2020.07.09.20149864>

- 256 8. Grossberg AN, Koza LA, Ledreux A, Prusmack C, Krishnamurthy HK, Jayaraman V, et al.  
257 A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-  
258 positive symptomatic and asymptomatic patients. *Nat Commun.* déc 2021;12(1):740.
- 259 9. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, et al.  
260 Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to  
261 disease severity [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2020 juin [cité 31 août  
262 2020]. Disponible sur: <http://medrxiv.org/lookup/doi/10.1101/2020.06.03.20121525>
- 263 10. de Assis RR, Jain A, Nakajima R, Jasinskas A, Felgner J, Obiero JM, et al. Analysis of  
264 SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen  
265 Microarray [Internet]. *Immunology*; 2020 avr [cité 10 juin 2020]. Disponible sur:  
266 <http://biorxiv.org/lookup/doi/10.1101/2020.04.15.043364>
- 267 11. Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, et al. Evaluating  
268 SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe  
269 and mild COVID-19 cases using a Luminex bead-based assay. *Journal of Virological*  
270 *Methods.* 1 févr 2021;288:114025.
- 271 12. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence Homology  
272 and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to  
273 SARS-CoV-2. *Cell Host & Microbe.* avr 2020;27(4):671-680.e2.
- 274 13. Aubry A, Demey B, François C, Duverlie G, Castelain S, Helle F, et al. Longitudinal  
275 Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19  
276 Diagnosis. 2021;8.
- 277 14. Malbec R, Kimpston-Burkgren K, Vandenkoornhuysen E, Olivier C, Souplet V, Audebert C,  
278 et al. Agrodiag PorCoV: A multiplex immunoassay for the differential diagnosis of porcine  
279 enteric coronaviruses. *Journal of Immunological Methods.* août 2020;483:112808.

280

## 281 **Supporting information captions**

282 **Supplementary Table 1.** Mean Signal Intensity (MSI) of the antibody response to different antigens for  
283 hospitalized and non-hospitalized patients.

284 **Supplementary Table 2.** Correlation between individual antigen titers and neutralizing antibody titers.

Fig. 1





Fig. 2

A



B




Fig. 3






Fig. 4

